Document Type
Article
Publication Date
1-1-2024
Original Citation
Telpoukhovskaia M,
Murdy T,
Marola O,
Charland K,
MacLean M,
Luquez T,
Lish A,
Neuner S,
Dunn A,
Onos KD,
Wiley J,
Archer D,
Huentelman M,
Arnold M,
Menon V,
Goate A,
Van Eldik L,
Territo P,
Howell G,
Carter GW,
O'Connell K,
Kaczorowski C,
.
New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop. Alzheimers Dement (N Y). 2024;10(1):e12458
Keywords
JMG
JAX Source
Alzheimers Dement (N Y). 2024;10(1):e12458
ISSN
2352-8737
PMID
38469553
DOI
https://doi.org/10.1002/trc2.12458
Grant
Alzheimer’s Association, Grant/Award Numbers: AARF-22-971325, AARF-ZEN-21-846037; National Institute on Aging, Grant/Award Numbers: T32AG062409, RF1AG058942, RF1AG059093, U01AG061359, U19AG063744, R01AG069901, RF1AG064859, R01AG069930, P30AG072946, U01AG076480, U54AG054345, U19AG074866, RF1AG075701, U54AG065187, R21AG083299, RF1AG079125, U54AG054345, R01AG066831; National Center for Advancing Translational Sciences, Grant/Award Number: U24TR004440; National Institute on Drug Abuse, Grant/Award Number: U01DA051235; National Cancer Institute, Grant/Award Number: P30CA034196; National Eye Institute, Grant/Award Numbers: R01EY034988, R01EY011996
Abstract
INTRODUCTION: In September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field.
METHODS: During the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic.
RESULTS: The team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de-risk clinical pipeline, and (4) centralize data management.
DISCUSSION: In this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.
Comments
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.